Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe and effective aspirin products. PLx Pharma Inc., formerly known as Dipexium Pharmaceuticals Inc., is based in NEW YORK, United States. “
Several other research analysts have also weighed in on the stock. Redburn Partners upgraded shares of Dipexium Pharmaceuticals to an “outperform” rating in a research report on Tuesday, August 1st. UBS AG upgraded shares of Dipexium Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. Dipexium Pharmaceuticals has an average rating of “Hold” and a consensus target price of $9.63.
Dipexium Pharmaceuticals (NASDAQ PLXP) traded up 0.250% during midday trading on Tuesday, hitting $6.416. 2,198 shares of the stock traded hands. The company’s 50 day moving average is $6.53 and its 200-day moving average is $7.55. The company’s market cap is $55.74 million. Dipexium Pharmaceuticals has a one year low of $5.60 and a one year high of $126.72.
COPYRIGHT VIOLATION NOTICE: This report was published by Equities Focus and is the sole property of of Equities Focus. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.equitiesfocus.com/2017/10/05/zacks-investment-research-downgrades-dipexium-pharmaceuticals-inc-plxp-to-sell.html.
Institutional investors and hedge funds have recently modified their holdings of the business. Heritage Way Advisors LLC acquired a new position in Dipexium Pharmaceuticals during the second quarter worth about $197,000. University of Texas Investment Managment Co. acquired a new position in Dipexium Pharmaceuticals during the second quarter worth about $385,000. Finally, Susquehanna International Group LLP acquired a new position in Dipexium Pharmaceuticals during the second quarter worth about $1,413,000. Institutional investors own 19.68% of the company’s stock.
Dipexium Pharmaceuticals Company Profile
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.